Physician profile
Gregory J Cox
NPI 1306803796
$11,980.93
in general payments reported to CMS, 2019-2025
41 companies · $2,557 in 2025
The $2,557 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,238 · 2020: $914 · 2021: $1,205 · 2022: $1,403 · 2023: $1,635 · 2024: $2,030 · 2025: $2,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,122 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,121.54 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,485.33 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $954.01 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Regeneron Healthcare Solutions, INC. | $883.99 | 2019-2025 | Dupixent |
| Merz North America, INC. | $835.86 | 2019-2020 | |
| Janssen Biotech, INC. | $828.85 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $603.97 | 2019-2025 | |
| Lilly USA, LLC | $534.64 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $528.60 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Incyte Corporation | $467.52 | 2021-2025 | Opzelura |
| Amgen INC. | $433.46 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $408.97 | 2019-2025 | Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $399.14 | 2023-2025 | Zoryve |
| Genzyme Corporation | $342.97 | 2019-2024 | |
| Ucb, INC. | $279.40 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $264.16 | 2019-2025 | Jublia |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $261.56 | 2019-2025 | |
| Dermavant Sciences, INC. | $217.70 | 2022-2024 | Vtama |
| Biofrontera INC. | $155.14 | 2020-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $150.52 | 2019-2024 | |
| Botanix Sb INC | $131.04 | 2025 | Sofdra |
| Organon LLC | $86.90 | 2024-2025 | Vtama |
| Allergan, INC. | $79.22 | 2019-2020 | |
| Celgene Corporation | $72.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.50 | 2022-2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $69.01 | 2022-2023 | Sotyktu |
| Almirall LLC | $59.40 | 2019-2021 | |
| Epi Health, LLC | $51.26 | 2020-2022 | |
| Verrica Pharmaceuticals INC. | $44.45 | 2023-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $31.05 | 2021 | |
| Springworks Therapeutics, INC. | $26.81 | 2025 | Gomekli |
| Lnhc, INC | $26.36 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $25.92 | 2025 | |
| Aclaris Therapeutics, INC. | $25.06 | 2019 | |
| Prugen, INC. Pharmaceuticals | $23.31 | 2020 | |
| Encore Dermatology INC. | $22.10 | 2019 | |
| Dusa Pharmaceuticals, INC. | $19.38 | 2019 | |
| Kerecis Limited | $18.15 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Krystal Biotech INC | $18.11 | 2023 | Vyjuvek |
| Medtronic, INC. | $17.11 | 2023 | Venaseal |
| Fidia Pharma USA INC. | $13.85 | 2025 | Triluron, Hymovis |
| Helsinn Therapeutics (U.S.), INC. | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.